Measles Virus-Infected Stem Cells for Ovarian Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does exclude those on certain treatments like chemotherapy, immunotherapy, or biologic therapy within a few weeks before joining. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of this treatment for ovarian cancer?
Research shows that mesenchymal stem cells (MSCs) can protect the measles virus from being neutralized by the immune system, allowing it to effectively target and destroy ovarian cancer cells. Additionally, a study found that a modified measles virus used in patients with drug-resistant ovarian cancer was well tolerated and associated with promising survival rates, suggesting the potential effectiveness of this treatment.12345
Is the treatment using measles virus-infected stem cells generally safe for humans?
The treatment using measles virus-infected stem cells has been evaluated in clinical settings, and in one study involving patients with drug-resistant ovarian cancer, it was well tolerated with no dose-limiting toxicity observed. This suggests that the treatment is generally safe in humans, at least in the context of the studies conducted.12456
How is the treatment MV-NIS Infected Mesenchymal Stem Cells unique for ovarian cancer?
This treatment uses mesenchymal stem cells (special cells that can develop into different types of cells) to carry a modified measles virus directly to ovarian cancer cells, protecting the virus from being neutralized by the body's immune system. This approach is different because it combines the virus's ability to kill cancer cells with the stem cells' ability to target tumors, potentially making it more effective than using the virus alone.12478
What is the purpose of this trial?
This phase I/II trial studies the side effects and best dose of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) infected mesenchymal stem cells and to see how well it works in treating patients with ovarian, primary peritoneal or fallopian tube cancer that has come back. Mesenchymal stem cells may be able to carry tumor-killing substances directly to ovarian, primary peritoneal and fallopian tube cancer cells.
Research Team
Evanthia Galanis
Principal Investigator
Mayo Clinic
Eligibility Criteria
This trial is for patients with recurrent ovarian, primary peritoneal or fallopian tube cancer who have previously been treated with platinum and taxanes. Participants must have adequate organ function, an ECOG performance status of 0-2, a life expectancy of at least 12 weeks, and no history of certain other conditions like severe allergies to measles vaccine or immunodeficiency.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive oncolytic measles virus encoding thyroidal sodium iodide symporter intraperitoneally over 30 minutes on day 1 of cycle 1 and MV-NIS infected mesenchymal stem cells IP over 30 minutes of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion, with follow-up every 6 months for up to 5 years.
Treatment Details
Interventions
- Mesenchymal Stem Cell Transplantation
- MV-NIS Infected Mesenchymal Stem Cells
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
National Cancer Institute (NCI)
Collaborator